Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2020

21.05.2020 | Clinical Study

Molecular characteristics and clinical features of multifocal glioblastoma

verfasst von: Antonio Dono, Emily Wang, Victor Lopez-Rivera, Arvind V. Ramesh, Nitin Tandon, Leomar Y. Ballester, Yoshua Esquenazi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glioblastomas (GBMs) usually occur as a solitary lesion; however, about 0.5–35% present with multiple lesions (M-GBM). The genetic landscape of GBMs have been thoroughly investigated; nevertheless, differences between M-GBM and single-foci GBM (S-GBM) remains unclear. The present study aimed to determine differences in clinical and molecular characteristics between M-GBM and S-GBM.

Methods

A retrospective review of multifocal/multicentric infiltrative gliomas (M-IG) from our institutional database was performed. Demographics, clinical, radiological, and genetic features were obtained and compared between M-GBM IDH-wild type (IDH-WT) vs 193 S-GBM IDH-WT. Mutations were examined by a targeted next-generation sequencing assay interrogating 315 genes.

Results

33M-IG were identified from which 94% were diagnosed as M-GBM IDH-WT, the remaining 6% were diagnosed as astrocytomas IDH-mutant. M-GBM and S-GBM comparison revealed that EGFR alterations were more frequent in M-GBM (65% vs 42% p = 0.019). Furthermore, concomitant EGFR/PTEN alterations were more common in M-GBM vs. S-GBM (36% vs 19%) as well as compared to TCGA (21%). No statistically significant differences in overall survival were observed between M-GBM and S-GBM; however, within the M-GBM cohort, patients harboring KDR alterations had a worse survival (KDR-altered 6.7 vs KDR-WT 16.6 months, p = 0.038).

Conclusions

The results of the present study demonstrate that M-GBM genetically resembles S-GBM, however, M-GBM harbor higher frequency of EGFR alterations and co-occurrence of EGFR/PTEN alterations, which may account for their highly malignant and invasive phenotype. Further study of genetic alterations including differences between multifocal and multicentric GBMs are warranted, which may identify potential targets for this aggressive tumor.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
33.
Zurück zum Zitat Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman E, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain E, Blot V, Ansell PJ, Samanta S, Kundu MG, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson R, Gedye C, Lebrun-Frenay C, Wick A, Curran WJ, Mehta M (2019) Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM). In: Paper presented at the annual meeting of Society of Neuro-Oncology, Phoenix, AZ Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman E, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain E, Blot V, Ansell PJ, Samanta S, Kundu MG, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson R, Gedye C, Lebrun-Frenay C, Wick A, Curran WJ, Mehta M (2019) Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM). In: Paper presented at the annual meeting of Society of Neuro-Oncology, Phoenix, AZ
Metadaten
Titel
Molecular characteristics and clinical features of multifocal glioblastoma
verfasst von
Antonio Dono
Emily Wang
Victor Lopez-Rivera
Arvind V. Ramesh
Nitin Tandon
Leomar Y. Ballester
Yoshua Esquenazi
Publikationsdatum
21.05.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03539-z

Weitere Artikel der Ausgabe 2/2020

Journal of Neuro-Oncology 2/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.